Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN PEDIATRIC versus BACTOCILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN PEDIATRIC versus BACTOCILL.
AMOXICILLIN PEDIATRIC vs BACTOCILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). It blocks the transpeptidation step in peptidoglycan cross-linking, leading to cell lysis and death.
BACTOCILL (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibitors. Active against Staphylococcus aureus and other gram-positive bacteria.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours for adults.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in children with normal renal function; prolonged to 7-21 hours in anuria.
0.5-0.8 hours; prolonged to 2-4 hours in severe renal impairment
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; biliary: minor (<10%); fecal: <5%.
Renal: 60-70% unchanged; biliary: 20-30% as active metabolite; fecal: 5-10%
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic